PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32828944-12	2020	SIGNIFICANCE: Raloxifene has effects on inhibiting atherosclerosis development, the underlying mechanisms might involve in inhibiting inflammation-related IL-6/STAT3 signaling pathway.	Raloxifene Hydrochloride	14-24	interleukin 6	Mus musculus	155-159	
32940862-10	2021	We also found that treatment with raloxifene inhibited the release of IL-6 and suppressed the phosphorylation of STAT3Y705 in PDAC cells.	Raloxifene Hydrochloride	34-44	interleukin 6	Mus musculus	70-74	
32940862-12	2021	CONCLUSIONS: Inhibition of ERbeta and the IL-6/gp130/STAT3 signaling pathway by raloxifene leads to potent reduction of PDAC growth in vitro and in vivo.	Raloxifene Hydrochloride	80-90	interleukin 6	Mus musculus	42-46	
32828944-0	2020	Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE-/- mice.	Raloxifene Hydrochloride	0-10	interleukin 6	Mus musculus	20-24	
32828944-2	2020	Our previous studies found that Raloxifene targeted against IL-6/GP130 protein-protein interface and inhibited STAT3 phosphorylation induced by IL-6 in cancer cells.	Raloxifene Hydrochloride	32-42	interleukin 6	Mus musculus	60-64	
32828944-2	2020	Our previous studies found that Raloxifene targeted against IL-6/GP130 protein-protein interface and inhibited STAT3 phosphorylation induced by IL-6 in cancer cells.	Raloxifene Hydrochloride	32-42	interleukin 6	Mus musculus	144-148	
32828944-3	2020	However, whether Raloxifene could suppress IL-6/STAT3 signaling pathway and attenuate atherosclerosis in high-fat diet (HFD)-induced mice remains unknown.	Raloxifene Hydrochloride	17-27	interleukin 6	Mus musculus	43-47	
32828944-9	2020	Histological analysis showed that the expression of IL-6, P-STAT3, ICAM-1, VCAM-1, CD68 and alpha-SMA were significantly decreased in the Raloxifene intervention group compared to HFD group.	Raloxifene Hydrochloride	138-148	interleukin 6	Mus musculus	52-56	
32828944-10	2020	Moreover, we observed that IL-6 increased migration and cell viability of VSMCs and RAW264.7 cells, while Raloxifene treatment decreased migration and reduced cell viability of VSMCs and RAW264.7 cells stimulated by IL-6.	Raloxifene Hydrochloride	106-116	interleukin 6	Mus musculus	216-220	
33824698-0	2021	Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene.	Raloxifene Hydrochloride	144-154	interleukin 6	Mus musculus	119-123	
18435803-9	2008	The proinflammatory cytokine IL-6 was down-regulated in raloxifene-treated mice compared with controls.	Raloxifene Hydrochloride	56-66	interleukin 6	Mus musculus	29-33	
11856644-12	2002	Consistent with decreased osteoclastogenesis, raloxifene inhibited the mRNA expression of interleukin (IL)-1beta and IL-6 at a low concentration, but not at a high concentration, whereas 17beta-estradiol had similar effects on IL-6 and inhibited IL-1beta at both concentrations.	Raloxifene Hydrochloride	46-56	interleukin 6	Mus musculus	117-121	
11856644-12	2002	Consistent with decreased osteoclastogenesis, raloxifene inhibited the mRNA expression of interleukin (IL)-1beta and IL-6 at a low concentration, but not at a high concentration, whereas 17beta-estradiol had similar effects on IL-6 and inhibited IL-1beta at both concentrations.	Raloxifene Hydrochloride	46-56	interleukin 6	Mus musculus	227-231	
33824698-10	2021	Conclusion: Inflammation and IL-6/STAT3 signaling were activated in TAC-induced HF in mice, while sustained IL-6 incubation elicited oxidative stress and mitophagy-related protein increase in H9c2 myoblasts, all of which were inhibited by raloxifene.	Raloxifene Hydrochloride	239-249	interleukin 6	Mus musculus	108-112	
33824698-7	2021	Importantly, IL-6/gp130/STAT3 inhibition by raloxifene alleviated TAC-induced myocardial inflammation, cardiac remodeling, and dysfunction.	Raloxifene Hydrochloride	44-54	interleukin 6	Mus musculus	13-17	
33824698-9	2021	Sustained IL-6 stimulation increased intracellular reactive oxygen species, repressed mitochondrial membrane potential (MMP), decreased intracellular content of ATP, and led to decreased SOD activity, an increase in iNOS protein expression, and increased protein expression of Pink1, Parkin, and Bnip3 involving in mitophagy, all of which were reversed by raloxifene.	Raloxifene Hydrochloride	356-366	interleukin 6	Mus musculus	10-14